Associations of Microbleeds and Their Topography With Imaging and CSF Biomarkers of Alzheimer Pathology in Individuals With Down Syndrome.
Humans
Down Syndrome
/ cerebrospinal fluid
Female
Male
Middle Aged
Cross-Sectional Studies
Biomarkers
/ cerebrospinal fluid
Cerebral Hemorrhage
/ diagnostic imaging
Alzheimer Disease
/ cerebrospinal fluid
Amyloid beta-Peptides
/ cerebrospinal fluid
tau Proteins
/ cerebrospinal fluid
Adult
Magnetic Resonance Imaging
Aged
Apolipoproteins E
/ genetics
Neurofilament Proteins
/ cerebrospinal fluid
Journal
Neurology
ISSN: 1526-632X
Titre abrégé: Neurology
Pays: United States
ID NLM: 0401060
Informations de publication
Date de publication:
27 Aug 2024
27 Aug 2024
Historique:
medline:
29
7
2024
pubmed:
29
7
2024
entrez:
29
7
2024
Statut:
ppublish
Résumé
Cerebral hemorrhages are an exclusion criterion and potential adverse effect of antiamyloid agents. It is, therefore, critical to characterize the natural history of cerebral microbleeds in populations genetically predisposed to Alzheimer disease (AD), such as Down syndrome (DS). We aimed to assess microbleed emergence in adults with DS across the AD spectrum, defining their topography and associations with clinical variables, cognitive outcomes, and fluid and neuroimaging biomarkers. This cross-sectional study included participants aged 18 years or older from the Down-Alzheimer Barcelona Neuroimaging Initiative and Sant Pau Initiative on Neurodegeneration with T1-weighted and susceptibility-weighted images. Participants underwent comprehensive assessments, including apolipoprotein E ( We included 276 individuals with DS and 158 healthy euploid controls (mean age = 47.8 years, 50.92% female). Individuals with DS were more likely to have microbleeds than controls (20% vs 8.9%, In participants with DS, microbleeds present with a posterior, lobar predominance, are associated with disease severity, but do not affect cognitive performance. These results suggest an interplay between AD pathology and vascular lesions, implicating microbleeds as a risk factor limiting the use of antiamyloid agents in this population.
Sections du résumé
BACKGROUND AND OBJECTIVES
OBJECTIVE
Cerebral hemorrhages are an exclusion criterion and potential adverse effect of antiamyloid agents. It is, therefore, critical to characterize the natural history of cerebral microbleeds in populations genetically predisposed to Alzheimer disease (AD), such as Down syndrome (DS). We aimed to assess microbleed emergence in adults with DS across the AD spectrum, defining their topography and associations with clinical variables, cognitive outcomes, and fluid and neuroimaging biomarkers.
METHODS
METHODS
This cross-sectional study included participants aged 18 years or older from the Down-Alzheimer Barcelona Neuroimaging Initiative and Sant Pau Initiative on Neurodegeneration with T1-weighted and susceptibility-weighted images. Participants underwent comprehensive assessments, including apolipoprotein E (
RESULTS
RESULTS
We included 276 individuals with DS and 158 healthy euploid controls (mean age = 47.8 years, 50.92% female). Individuals with DS were more likely to have microbleeds than controls (20% vs 8.9%,
DISCUSSION
CONCLUSIONS
In participants with DS, microbleeds present with a posterior, lobar predominance, are associated with disease severity, but do not affect cognitive performance. These results suggest an interplay between AD pathology and vascular lesions, implicating microbleeds as a risk factor limiting the use of antiamyloid agents in this population.
Identifiants
pubmed: 39074338
doi: 10.1212/WNL.0000000000209676
doi:
Substances chimiques
Biomarkers
0
Amyloid beta-Peptides
0
tau Proteins
0
Apolipoproteins E
0
neurofilament protein L
0
Neurofilament Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e209676Références
Nature. 2020 May;581(7806):71-76
pubmed: 32376954
Brain. 2023 Nov 2;146(11):4414-4424
pubmed: 37280110
Lancet. 2020 Jun 27;395(10242):1988-1997
pubmed: 32593336
World Psychiatry. 2013 Jun;12(2):92-8
pubmed: 23737408
Mayo Clin Proc. 2020 Jun;95(6):1195-1205
pubmed: 32498775
Acta Neuropathol Commun. 2017 Dec 01;5(1):93
pubmed: 29195510
Neurobiol Aging. 2013 Nov;34(11):2488-94
pubmed: 23731952
Nat Rev Neurol. 2019 Mar;15(3):135-147
pubmed: 30733618
Neurobiol Aging. 2015 Oct;36(10):2702-8
pubmed: 26239176
Alzheimers Dement. 2018 Nov;14(11):1482-1492
pubmed: 29792871
Alzheimers Dement. 2011 Jul;7(4):367-85
pubmed: 21784348
Nat Rev Neurol. 2018 Aug;14(8):457-469
pubmed: 29985474
Brain. 2011 Feb;134(Pt 2):335-44
pubmed: 21257651
Hum Brain Mapp. 2003 Aug;19(4):224-47
pubmed: 12874777
Front Neurol. 2021 Apr 06;12:543866
pubmed: 33889121
J Stroke Cerebrovasc Dis. 2008 Sep;17(5):303-11
pubmed: 18755411
Neurology. 2021 Mar 23;96(12):e1632-e1645
pubmed: 33495373
Alzheimers Dement. 2017 Nov;13(11):1251-1260
pubmed: 28463681
AJNR Am J Neuroradiol. 2015 Sep;36(9):1635-41
pubmed: 26228889
Neurology. 2023 Nov 7;101(19):e1837-e1849
pubmed: 37586881
Mech Ageing Dev. 1988 May;43(2):99-136
pubmed: 2969441
JAMA Netw Open. 2022 May 2;5(5):e2212910
pubmed: 35604690
Neurology. 2022 Jun 14;98(24):1021-1022
pubmed: 35470138
Brain Commun. 2023 Mar 17;5(2):fcad074
pubmed: 37056479
Alzheimers Dement (N Y). 2018 Dec 13;4:703-713
pubmed: 30581976
Cerebrovasc Dis. 2015;39(2):138-43
pubmed: 25661058
Ann Neurol. 2005 Sep;58(3):459-62
pubmed: 16130107
Arch Neurol. 2008 Jun;65(6):790-5
pubmed: 18541799
Nat Rev Neurol. 2020 Jan;16(1):30-42
pubmed: 31827267
Neuroimage. 2011 Feb 1;54(3):2033-44
pubmed: 20851191
Am J Intellect Dev Disabil. 2015 Nov;120(6):481-9
pubmed: 26505869
Stroke. 2020 Jan;51(1):202-208
pubmed: 31726962
JAMA Neurol. 2021 Aug 1;78(8):937-947
pubmed: 34228042
Dev Neurobiol. 2019 Jul;79(7):716-737
pubmed: 31278851
Neurosci Lett. 2007 May 23;419(1):18-22
pubmed: 17482358
Neurobiol Aging. 2015 Dec;36(12):3140-3151
pubmed: 26410308
Neuroimage. 2006 Jul 1;31(3):1116-28
pubmed: 16545965
Neurology. 2014 Apr 8;82(14):1266-73
pubmed: 24623839
Neurology. 2013 Jul 16;81(3):292-300
pubmed: 23858411
Biometrics. 1977 Mar;33(1):159-74
pubmed: 843571
Radiology. 2018 Apr;287(1):11-28
pubmed: 29558307
Int J Stroke. 2018 Jul;13(5):454-468
pubmed: 29338604
Rev Neurol. 2013 Oct 16;57(8):337-46
pubmed: 24081888
Stroke. 2009 Nov;40(11):3455-60
pubmed: 19762705
Ann Neurol. 2020 Dec;88(6):1165-1177
pubmed: 32944999
Lancet Neurol. 2022 Aug;21(8):714-725
pubmed: 35841910